Oracle (NYSE:ORCL) was in focus on Thursday as investment firm Argus raised its earnings estimates and upgraded the IT tech giant after it reported fiscal third-quarter results. Shares were flat in ...

Builds on Oracle's Endeavor to Provide an Integrated Pharmacovigilance Suite That Supports End-to-End Drug Safety Processes Across Clinical Development and Post-Market Surveillance As part of its ...

NEWARK, DE — QPS Holdings, LLC has implemented Oracle Argus, a widely used pharmacovigilance platform, in a move aimed at strengthening patient safety oversight and regulatory compliance across its ...

QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier ...

Contract Research Organization aims to improve data management, accuracy, and safety with Oracle's AI-powered pharmacovigilance platform AUSTIN, Texas, July 8, 2025 /PRNewswire/ -- Contract Research ...

US-based contract research organisation QPS Holdings (QPS) has implemented a new clinical trial pharmacovigilance system, Oracle Argus, to advance safety case management in clinical trials. The ...

SAN DIEGO, Oct. 25, 2012 /PRNewswire/ -- Synteract, a leading full service contract research organization (CRO), has implemented two Oracle® Argus 7.0 modules to its pharmacovigilance technology ...

Argus, a financial analysis firm, has upgraded its price target for Oracle Corporation (NYSE: NYSE:ORCL) from $159.00 to $176.00 while maintaining a Buy rating on the shares. The firm highlighted ...

Argus analyst Joseph Bonner raised the firm’s price target on Oracle (ORCL) to $200 from $176 and keeps a Buy rating on the shares after its Q2 results. The company is in the enviable position of ...

AUSTIN, Texas, July 8, 2025 /PRNewswire/ -- Contract Research Organization (CRO), PrimeVigilance, is significantly enhancing its service offerings with Oracle Argus. Delivering the full lifecycle of ...